CGH
VNDA icon

Crossmark Global Holdings’s Vanda Pharmaceuticals VNDA Stock Holding History

Crossmark Global Holdings’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-8,583
Closed -$224K – 1408
2018
Q4 		$224K Buy
+8,583
New +$202K 0.01% 1239

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Crossmark Global Holdings's VNDA Position: Q1 2019 in Review

Crossmark Global Holdings sold out of Vanda Pharmaceuticals (VNDA) in Q1 2019, closing a stake of 8,583 shares — an estimated $224K sold.

Crossmark Global Holdings first reported a position in VNDA in Q4 2018 and held it in 1 quarter. The position peaked at $224K in Q4 2018. 179 funds tracked by Wall St. Rank hold VNDA as of Q1 2019.

  • Crossmark Global Holdings reported no remaining Vanda Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Crossmark Global Holdings sold 8,583 Vanda Pharmaceuticals shares in Q1 2019, an estimated $224K.
  • Crossmark Global Holdings first reported a position in Vanda Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Crossmark Global Holdings's Vanda Pharmaceuticals position peaked at $224K in Q4 2018.
  • 179 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2019.

Based on Crossmark Global Holdings's 13F filing for Q1 2019, filed 2 May 2019.